|
CN118271463A
(zh)
|
2014-12-05 |
2024-07-02 |
纪念斯隆-凯特琳癌症中心 |
靶向g-蛋白偶联受体的嵌合抗原受体及其用途
|
|
BR112017011932A8
(pt)
*
|
2014-12-05 |
2022-11-08 |
Memorial Sloan Kettering Cancer Center |
Anticorpos direcionados a receptor acoplado a proteína g e métodos de uso
|
|
MX2018004721A
(es)
|
2015-10-23 |
2018-07-06 |
Eureka Therapeutics Inc |
Construcciones quimericas anticuerpo/receptor de celulas t y usos de las mismas.
|
|
TWI781108B
(zh)
*
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
EP3548055A4
(en)
|
2016-12-02 |
2020-08-19 |
University of Southern California |
SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
|
|
SG11201907321TA
(en)
*
|
2017-02-07 |
2019-09-27 |
Daiichi Sankyo Co Ltd |
Anti-gprc5d antibody and molecule comprising the antibody
|
|
JP7538601B2
(ja)
|
2017-04-26 |
2024-08-22 |
ユーリカ セラピューティックス， インコーポレイテッド |
キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用
|
|
KR20250016455A
(ko)
|
2017-08-09 |
2025-02-03 |
주노 쎄러퓨티크스 인코퍼레이티드 |
유전자 조작된 세포 조성물 및 관련 조성물의 제조 방법
|
|
EP3664835B1
(en)
|
2017-08-09 |
2024-10-23 |
Juno Therapeutics, Inc. |
Methods and compositions for preparing genetically engineered cells
|
|
MA50079A
(fr)
|
2017-09-07 |
2020-07-15 |
Juno Therapeutics Inc |
Procédés d'identification de caractéristiques cellulaires relatives à des réponses associées à une thérapie cellulaire
|
|
EP3693012A4
(en)
|
2017-10-05 |
2021-07-21 |
Daiichi Sankyo Company, Limited |
CYTOTOXIC T-CELL DEPLOYMENT COMPOSITION
|
|
WO2019089858A2
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
|
US11564946B2
(en)
|
2017-11-01 |
2023-01-31 |
Juno Therapeutics, Inc. |
Methods associated with tumor burden for assessing response to a cell therapy
|
|
EP3704229B1
(en)
|
2017-11-01 |
2023-12-20 |
Juno Therapeutics, Inc. |
Process for producing a t cell composition
|
|
US12258580B2
(en)
|
2017-11-01 |
2025-03-25 |
Juno Therapeutics, Inc. |
Process for generating therapeutic compositions of engineered cells
|
|
PT3703750T
(pt)
|
2017-11-01 |
2025-01-17 |
Memorial Sloan Kettering Cancer Center |
Recetores de antigénio quimérico específicos para o antigénio de maturação das células b e polinucleótidos codificantes
|
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
|
CN119193493A
(zh)
|
2017-12-08 |
2024-12-27 |
朱诺治疗学股份有限公司 |
生产工程化t细胞组合物的过程
|
|
US12161670B2
(en)
|
2017-12-08 |
2024-12-10 |
Juno Therapeutics, Inc. |
Phenotypic markers for cell therapy and related methods
|
|
MX2020005907A
(es)
|
2017-12-08 |
2020-10-19 |
Juno Therapeutics Inc |
Formulacion de medio libre de suero para cultivar celulas y metodos de uso de la misma.
|
|
TWI829667B
(zh)
*
|
2018-02-09 |
2024-01-21 |
瑞士商赫孚孟拉羅股份公司 |
結合gprc5d之抗體
|
|
EP3774919A4
(en)
*
|
2018-03-30 |
2021-12-29 |
Eureka Therapeutics, Inc. |
Constructs targeting cd22 and uses thereof
|
|
US12473342B2
(en)
|
2018-04-27 |
2025-11-18 |
The Trustees Of The University Of Pennsylvania |
Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
|
|
UA130542C2
(uk)
*
|
2018-05-16 |
2026-03-18 |
Янссен Байотек, Інк. |
Антитіло до cd38 та терапевтичний засіб, який перенаправляє т-клітини, для лікування множинної мієломи у суб'єкта
|
|
CN112805378A
(zh)
|
2018-08-09 |
2021-05-14 |
朱诺治疗学股份有限公司 |
用于评估整合核酸的方法
|
|
US12516099B2
(en)
|
2018-08-09 |
2026-01-06 |
Juno Therapeutics, Inc. |
Processes for generating engineered cells and compositions thereof
|
|
SG11202104355SA
(en)
|
2018-10-31 |
2021-05-28 |
Juno Therapeutics Gmbh |
Methods for selection and stimulation of cells and apparatus for same
|
|
EP3873937A2
(en)
|
2018-11-01 |
2021-09-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for g protein-coupled receptor class c group 5 member d (gprc5d)
|
|
MA54078A
(fr)
|
2018-11-01 |
2021-09-15 |
Juno Therapeutics Inc |
Méthodes pour le traitement au moyen de récepteurs antigéniques chimériques spécifiques de l'antigene de maturation des lymphocytes b
|
|
PT3886875T
(pt)
|
2018-11-30 |
2024-06-27 |
Juno Therapeutics Inc |
Métodos para tratamento utilizando terapia celular adotiva
|
|
CA3136742A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified cd247 locus, related polynucleotides and methods
|
|
WO2020223535A1
(en)
|
2019-05-01 |
2020-11-05 |
Juno Therapeutics, Inc. |
Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods
|
|
KR20220034782A
(ko)
|
2019-06-12 |
2022-03-18 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 매개 세포 독성 요법 및 친생존 ｂｃｌ2 패밀리 단백질 억제제의 병용 요법
|
|
EP3983447A4
(en)
*
|
2019-06-14 |
2023-06-28 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against muc1 and methods of use thereof
|
|
SG11202111943UA
(en)
|
2019-07-02 |
2021-11-29 |
Hutchinson Fred Cancer Res |
Recombinant ad35 vectors and related gene therapy improvements
|
|
CN114174338A
(zh)
|
2019-07-31 |
2022-03-11 |
豪夫迈·罗氏有限公司 |
与gprc5d结合的抗体
|
|
CA3248329A1
(en)
|
2019-07-31 |
2025-11-29 |
F. Hoffmann-La Roche Ag |
Antibodies binding to gprc5d
|
|
CN114555112A
(zh)
|
2019-08-22 |
2022-05-27 |
朱诺治疗学股份有限公司 |
T细胞疗法和zeste增强子同源物2(ezh2)抑制剂的组合疗法及相关方法
|
|
KR20220101641A
(ko)
|
2019-10-30 |
2022-07-19 |
주노 테라퓨틱스 게엠베하 |
세포 선택 및/또는 자극 장치 및 사용 방법
|
|
EP4069742A1
(en)
*
|
2019-12-06 |
2022-10-12 |
Juno Therapeutics, Inc. |
Anti-idiotypic antibodies to gprc5d-targeted binding domains and related compositions and methods
|
|
JP2023512209A
(ja)
|
2020-01-28 |
2023-03-24 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞形質導入のための方法
|
|
UY39174A
(es)
*
|
2020-04-17 |
2021-10-29 |
Janssen Biotech Inc |
Poblaciones de glicoproteínas biosintéticas
|
|
KR20230024283A
(ko)
|
2020-05-13 |
2023-02-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
임상 반응과 관련된 특징을 식별하는 방법 및 이의 용도
|
|
JP2023531531A
(ja)
|
2020-06-26 |
2023-07-24 |
ジュノ セラピューティクス ゲーエムベーハー |
組換え受容体を条件付きで発現する操作されたｔ細胞、関連ポリヌクレオチド、および方法
|
|
EP4240756A1
(en)
|
2020-11-04 |
2023-09-13 |
Juno Therapeutics, Inc. |
Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods
|
|
PT4274851T
(pt)
*
|
2021-01-05 |
2026-02-13 |
Lanova Medicines Dev Co Ltd |
Anticorpos monoclonais anti-gprc5d e utilizações destes
|
|
EP4274851B1
(en)
*
|
2021-01-05 |
2025-11-26 |
Lanova Medicines Development Co., Ltd. |
Anti-gprc5d monoclonal antibodies and uses thereof
|
|
JP2024507180A
(ja)
|
2021-02-16 |
2024-02-16 |
ヤンセン ファーマシューティカ エヌ．ベー． |
Ｂｃｍａ、ｇｐｒｃ５ｄ、及びｃｄ３を標的とする三重特異的抗体
|
|
CN117693508A
(zh)
|
2021-03-03 |
2024-03-12 |
朱诺治疗学股份有限公司 |
T细胞疗法和dgk抑制剂的组合
|
|
CN117321200A
(zh)
|
2021-03-22 |
2023-12-29 |
朱诺治疗学股份有限公司 |
评估病毒载体颗粒效力的方法
|
|
AU2022241654A1
(en)
|
2021-03-22 |
2023-09-28 |
Juno Therapeutics, Inc. |
Methods of determining potency of a therapeutic cell composition
|
|
JP2024517863A
(ja)
|
2021-05-06 |
2024-04-23 |
ジュノ・セラピューティクス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
細胞を刺激し、形質導入する方法
|
|
WO2022247804A1
(zh)
*
|
2021-05-23 |
2022-12-01 |
上海祥耀生物科技有限责任公司 |
抗gprc5d抗体、其制备方法与用途
|
|
WO2023030272A1
(zh)
*
|
2021-08-30 |
2023-03-09 |
原启生物科技(上海)有限责任公司 |
抗gprc5d抗原结合蛋白及其用途
|
|
CN118159565A
(zh)
*
|
2021-11-05 |
2024-06-07 |
正大天晴药业集团股份有限公司 |
结合gprc5d的抗体及其用途
|
|
IL312728A
(en)
|
2021-11-30 |
2024-07-01 |
Daiichi Sankyo Co Ltd |
Protease-cleavable masked antibodies
|
|
CN116375867A
(zh)
*
|
2021-12-31 |
2023-07-04 |
康源博创生物科技(北京)有限公司 |
抗gprc5d抗体及其应用
|
|
JP2025504795A
(ja)
*
|
2022-01-10 |
2025-02-19 |
ナンチン リーズ バイオラブス カンパニー，リミティド |
抗体及びその用途
|
|
WO2023134718A1
(zh)
*
|
2022-01-14 |
2023-07-20 |
原启生物科技(上海)有限责任公司 |
靶向gprc5d的嵌合抗原受体及其用途
|
|
KR20240137075A
(ko)
|
2022-01-28 |
2024-09-19 |
주노 쎄러퓨티크스 인코퍼레이티드 |
세포 조성물의 제조 방법
|
|
TW202342106A
(zh)
|
2022-02-09 |
2023-11-01 |
日商第一三共股份有限公司 |
環境應答性遮蔽抗體及其利用
|
|
US20250297282A1
(en)
|
2022-05-05 |
2025-09-25 |
Juno Therapeutics Gmbh |
Viral-binding protein and related reagents, articles, and methods of use
|
|
WO2023220655A1
(en)
|
2022-05-11 |
2023-11-16 |
Celgene Corporation |
Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
|
|
EP4532695A1
(en)
|
2022-05-25 |
2025-04-09 |
Celgene Corporation |
Methods of manufacturing t cell therapies
|
|
CN119278217A
(zh)
*
|
2022-05-27 |
2025-01-07 |
德琪(杭州)生物有限公司 |
新型抗gprc5d抗体、结合gprc5d和cd3的双特异性抗原结合分子以及其用途
|
|
JP2025525439A
(ja)
|
2022-06-30 |
2025-08-05 |
インダプタ セラピューティクス インコーポレイテッド |
操作されたナチュラルキラー（ｎｋ）細胞と抗体療法との組み合わせおよび関連する方法
|
|
CN119698434A
(zh)
*
|
2022-07-21 |
2025-03-25 |
山东先声生物制药有限公司 |
抗gprc5d纳米抗体及其应用
|
|
JP2025525937A
(ja)
|
2022-08-05 |
2025-08-07 |
ジュノー セラピューティクス インコーポレイテッド |
Ｇｐｒｃ５ｄおよびｂｃｍａに特異的なキメラ抗原受容体
|
|
EP4583876A1
(en)
|
2022-09-08 |
2025-07-16 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and continuous or intermittent dgk inhibitor dosing
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
JP2026504491A
(ja)
|
2023-02-03 |
2026-02-05 |
ツェー３エス２ ゲーエムベーハー |
操作された免疫細胞の非ウイルス的製造のための方法
|
|
WO2024220588A1
(en)
|
2023-04-18 |
2024-10-24 |
Juno Therapeutics, Inc. |
Cytotoxicity assay for assessing potency of therapeutic cell compositions
|
|
KR20260026101A
(ko)
|
2023-05-23 |
2026-02-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
T 세포의 활성화 마커 및 t 세포 활성화를 평가하는 방법
|
|
US12286475B2
(en)
|
2023-07-31 |
2025-04-29 |
Sanofi |
Anti-GPRC5D antibodies and compositions
|
|
WO2025059362A1
(en)
|
2023-09-13 |
2025-03-20 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
US20250127728A1
(en)
|
2023-10-05 |
2025-04-24 |
Capstan Therapeutics, Inc. |
Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
|
|
WO2025076472A1
(en)
|
2023-10-06 |
2025-04-10 |
Juno Therapeutics, Inc. |
Combination therapies with a cell therapy expressing a gprc5d-targeting car and related methods and uses
|
|
WO2025134050A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of multiple myeloma
|
|
WO2025134049A1
(en)
|
2023-12-21 |
2025-06-26 |
Janssen Biotech, Inc |
Trispecific antibody targeting bcma, gprc5d and cd3 for the treatment of al amyloidosis
|
|
WO2025147545A1
(en)
|
2024-01-03 |
2025-07-10 |
Juno Therapeutics, Inc. |
Lipid nanoparticles for delivery of nucleic acids and related methods and uses
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
US20260041768A1
(en)
|
2024-05-03 |
2026-02-12 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025231372A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2026020055A2
(en)
|
2024-07-18 |
2026-01-22 |
Juno Therapeutics, Inc. |
Methods for assessing exosomes in a cell composition and related uses
|
|
WO2026025092A1
(en)
|
2024-07-26 |
2026-01-29 |
Juno Therapeutics, Inc. |
Synthetic promoters for t cell expression
|
|
WO2026044177A1
(en)
*
|
2024-08-23 |
2026-02-26 |
Janssen Biotech, Inc. |
Methods of treatment with gprc5d antibodies with enhanced effector function
|